Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Stereotactische radiotherapie en abirateronacetaat voor oligometastatisch CRPC
dec 2023 | Radiotherapie, Uro-oncologie